AGC Biologics News and Resources

AGC Biologics, a global biopharmaceutical CDMO, has signed a development and manufacturing agreement with Adaptimmune to advance letetresgene autoleucel (lete-cel), an engineered TCR T-cell therapy targeting NY-ESO-1 positive solid tumours. The agreement includes process characterisation, stability studies, and manufacturing activities

Genenta Science has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master Services Agreement. This amendment includes the introduction of an exclusive GMP suite at AGC Biologics’ Cell and

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a collaboration with Pandorum Technologies to manufacture Kuragenx. Kuragenx, also known as the “liquid cornea,” is a combination biologic designed to treat advanced neurotrophic keratitis (NK), a

AGC Biologics has named Alberto Santagostino as its new Chief Executive Officer and President, marking a shift toward becoming what it calls “Your friendly CDMO expert.” Santagostino, who steps into the role with two decades of biopharma industry experience, brings

AGC Biologics announced that the U.S. Food and Drug Administration (FDA) approved three Biologics License Applications (BLAs) from a March 2024 inspection at its Seattle facility. The inspection, which covered three commercial biologics, resulted in the approval of two FC-fusion

AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO), announced a strategic service agreement with CompleCure to support the development of a novel anti-cancer therapeutic. The therapy, based on Antibody Mimetics Drug Conjugate (AMDC) technology, represents a new approach

NEC Bio Therapeutics, a German biotechnology firm based in Mannheim, is collaborating with AGC Biologics to enhance the production of NECVAX-NEO1. This vaccine, designed to be delivered orally, targets patient-specific tumor neoantigens using a bacteria-based DNA platform. It aims to

Essential Pharma has entered into a strategic agreement with AGC Biologics for the production of Hu14.18, a humanized monoclonal antibody. This antibody is currently under development for the treatment of high-risk neuroblastoma (HRNB), a rare and aggressive form of cancer that

AGC Biologics, a global biopharmaceutical CDMO, and BioConnection, a specialised contract manufacturing organisation (CMO), have announced a new partnership to provide comprehensive biopharmaceutical development and manufacturing services. This collaboration, effective from 22nd May 2024, aims to streamline drug substance and

AGC Biologics, a Seattle-based biopharma contract manufacturer, has announced plans to lay off just under 4% of its global workforce. The company, which employs more than 2,500 workers worldwide, confirmed in a statement that it has had to reduce positions